AĆIMOVIĆ, Ivana, Viktorie GABRIELOVÁ, Stanislava MARTÍNKOVÁ, Michal EID, Jakub VLAŽNÝ, Petr MORAVČÍK, Jan HLAVSA, Lukáš MORÁŇ, Riza Can CAKMAKCI, Peter STAŇO, Vladimír PROCHÁZKA, Zdeněk KALA, Jan TRNKA and Petr VAŇHARA. Ex-vivo 3D cellular models of pancreatic ductal adenocarcinoma: from embryonic development to precision oncology. PANCREAS. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2024. ISSN 0885-3177. Available from: https://dx.doi.org/10.1097/MPA.0000000000002393.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Ex-vivo 3D cellular models of pancreatic ductal adenocarcinoma: from embryonic development to precision oncology
Authors AĆIMOVIĆ, Ivana, Viktorie GABRIELOVÁ, Stanislava MARTÍNKOVÁ, Michal EID, Jakub VLAŽNÝ, Petr MORAVČÍK, Jan HLAVSA, Lukáš MORÁŇ, Riza Can CAKMAKCI, Peter STAŇO, Vladimír PROCHÁZKA, Zdeněk KALA, Jan TRNKA and Petr VAŇHARA.
Edition PANCREAS, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2024, 0885-3177.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30400 3.4 Medical biotechnology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.900 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1097/MPA.0000000000002393
UT WoS 999
Tags 14110212, 14110223, 14110230, 14110517
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 19/8/2024 13:00.
Abstract
Pancreas is a vital gland of gastro-intestinal system with exocrine and endocrine secretory functions, interweaved into essential metabolic circuitries of the human body. Pancreatic ductal adenocarcinoma (PDAC) represents one of the most lethal malignancies, with a five-year survival rate of 11%. This poor prognosis is primarily attributed to the absence of early symptoms, rapid metastatic dissemination, and the limited efficacy of current therapeutic interventions. Despite recent advancements in understanding the etiopathogenesis and treatment of PDAC, there remains a pressing need for improved individualized models, the identification of novel molecular targets, and the development of unbiased predictors of disease progression. Here we aim to explore the concept of precision medicine utilizing three-dimensional, patient-specific cellular models of pancreatic tumors and discuss their potential applications in uncovering novel druggable molecular targets and predicting clinical parameters for individual patients.
Links
MUNI/A/1558/2023, interní kód MUName: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit XI
Investor: Masaryk University
MUNI/A/1598/2023, interní kód MUName: Zdroje pro tkáňové inženýrství 14
Investor: Masaryk University, Resources pro tissue engineering 14
NU23-08-00241, research and development projectName: Vývoj ex-vivo buněčných modelů pro adenokarcinom pankreatu: markery a cíle pro precizní medicínu
Investor: Ministry of Health of the CR, Development of ex vivo cellular models for pancreatic adenocarcinoma: markers and targets for precision medicine, Subprogram 1 - standard
PrintDisplayed: 20/8/2024 22:21